Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) had its target price dropped by stock analysts at Barclays from $48.00 to $41.00 in a research note issued to investors on Monday, Benzinga reports. The firm presently has an "overweight" rating on the specialty pharmaceutical company's stock. Barclays's target price would indicate a potential upside of 62.50% from the company's current price.
Several other analysts have also weighed in on the company. Piper Sandler decreased their price target on Collegium Pharmaceutical from $43.00 to $28.00 and set a "neutral" rating on the stock in a report on Friday, November 6th. Needham & Company LLC lowered their price target on Collegium Pharmaceutical from $46.00 to $44.00 and set a "buy" rating for the company in a research report on Thursday, November 5th. Oppenheimer assumed coverage on shares of Collegium Pharmaceutical in a research note on Wednesday, September 23rd. They set an "outperform" rating and a $50.00 price objective for the company. Zacks Research raised shares of Collegium Pharmaceutical from a "strong sell" rating to a "strong-buy" rating in a research note on Thursday, October 15th. Finally, Leerink Partners started coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 9th. They set an "outperform" rating and a $45.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $44.00.
Get Our Latest Analysis on COLL
Collegium Pharmaceutical Trading Down 0.4%
NASDAQ COLL traded down $0.09 during trading hours on Monday, hitting $25.23. 39,323 shares of the company were exchanged, compared to its average volume of 581,390. The stock has a 50-day moving average price of $23.04 and a 200 day moving average price of $32.26. The company has a quick ratio of 0.87, a current ratio of 1.01 and a debt-to-equity ratio of 3.44. Collegium Pharmaceutical has a 52 week low of $21.43 and a 52 week high of $50.79. The stock has a market cap of $784.15 million, a PE ratio of 25.18, a price-to-earnings-growth ratio of 0.79 and a beta of 0.74.
Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.86 by $0.10. The business had revenue of $216.34 million for the quarter, compared to the consensus estimate of $216.03 million. Collegium Pharmaceutical had a return on equity of 85.14% and a net margin of 4.68%. The company's quarterly revenue was up 67.4% compared to the same quarter last year. During the same period in the prior year, the business posted $2.25 earnings per share. Analysts forecast that Collegium Pharmaceutical will post 6.42 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Collegium Pharmaceutical
Hedge funds and other institutional investors have recently modified their holdings of the business. Assetmark Inc. raised its position in shares of Collegium Pharmaceutical by 9.3% in the 1st quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company's stock worth $130,000 after acquiring an additional 335 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Collegium Pharmaceutical by 42.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company's stock worth $47,000 after buying an additional 418 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Collegium Pharmaceutical by 15.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,940 shares of the specialty pharmaceutical company's stock worth $132,000 after purchasing an additional 778 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Collegium Pharmaceutical by 20.6% during the first quarter. EverSource Wealth Advisors LLC now owns 5,035 shares of the specialty pharmaceutical company's stock worth $167,000 after purchasing an additional 861 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Collegium Pharmaceutical by 11.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 9,032 shares of the specialty pharmaceutical company's stock worth $300,000 after purchasing an additional 924 shares in the last quarter.
About Collegium Pharmaceutical
(
Get Free Report)
Collegium Pharmaceutical is a U.S.-based specialty pharmaceutical company focused on developing and commercializing medicines for pain management. Its portfolio includes Xtampza ER, an extended-release oxycodone product; Belbuca, a buprenorphine buccal film for chronic pain; and Nucynta, tapentadol tablets available in immediate- and extended-release formulations. The company also markets Symproic, a treatment for opioid-induced constipation. Collegium's products include extended-release and opioid medicines, and the company emphasizes responsible use and risk-mitigation measures in its commercial activities.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Collegium Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Collegium Pharmaceutical wasn't on the list.
While Collegium Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.